The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

Chromaderm

Status and phase: Completed; Phase 2

Conditions: Diabetic Nephropathy

Treatments: Drug: LY333531

Study type: Interventional

Funder types: Industry

Identifiers

NCT00044148

B7A-MC-MBDA

6249

Details and patient eligibility

About

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

Sex: All

Ages: 30+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus
• Greater than or equal to 30 years of age
• Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.

Exclusion criteria

• Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females
• B/P greater than 150 systolic and greater than 90 diastolic
• Hemoglobin Alc greater than 11%
• Liver Function Tests 2 times upper limit of normal
• Poor medical or psychiatric risk.